TRCT
GPCR icon

Tower Research Capital (TRC)’s Structure Therapeutics GPCR Stock Holding History

Tower Research Capital (TRC)’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.1K Buy
646
+605
+1,476% +$41.4K ﹤0.01% 3138
2025
Q4 		$2.85K Sell
41
-353
-90% -$14.4K ﹤0.01% 4465
2025
Q3 		$11K Sell
394
-504
-56% -$10K ﹤0.01% 3923
2025
Q2 		$18.6K Buy
898
+303
+51% +$6.66K ﹤0.01% 3723
2025
Q1 		$10.3K Sell
595
-3,481
-85% -$85.3K ﹤0.01% 3656
2024
Q4 		$111K Buy
4,076
+3,549
+673% +$126K ﹤0.01% 2098
2024
Q3 		$23.1K Buy
527
+158
+43% +$6.11K ﹤0.01% 3162
2024
Q2 		$14.5K Buy
369
+81
+28% +$3.33K ﹤0.01% 3944
2024
Q1 		$12.3K Sell
288
-775
-73% -$32.7K ﹤0.01% 3489
2023
Q4 		$43.3K Buy
1,063
+142
+15% +$8.14K ﹤0.01% 3223
2023
Q3 		$46.4K Buy
921
+854
+1,275% +$27.5K ﹤0.01% 2611
2023
Q2 		$2.79K Sell
67
-33
-33% -$925 ﹤0.01% 5152
2023
Q1 		$2K Buy
+100
New +$2.35K ﹤0.01% 5352

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Tower Research Capital (TRC)'s GPCR Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Structure Therapeutics (GPCR) stake by 1,476% in Q1 2026, buying an estimated $41.4K and bringing the position to 646 shares worth $31.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3138.

Tower Research Capital (TRC) first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $111K in Q4 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Tower Research Capital (TRC) held 646 shares of Structure Therapeutics worth $31.1K as of Q1 2026.
  • Tower Research Capital (TRC) bought 605 Structure Therapeutics shares in Q1 2026, an estimated $41.4K.
  • Structure Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3138 holding.
  • Tower Research Capital (TRC) first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Tower Research Capital (TRC)'s Structure Therapeutics position peaked at $111K in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.